Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT05036811
NCT05036811UnknownNot Applicable

HIV and Inflammatory or Autoimmune Disease: Rare Patients, Many Questions (MAIVIH)

Tourcoing Hospital1 site in 1 country400 target enrollmentStarted: June 7, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
400
Locations
1
Primary Endpoint
Number of patients living with HIV who have an inflammatory or autoimmune disease
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Follow-up registry of patients living with HIV who also have various inflammatory and autoimmune pathologies that may require immunosuppressive treatment.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient living with HIV
  • •Carrier of one or more of the following diseases:
  • •Sarcoidosis Multiple sclerosis Myasthenia gravis Crohn's disease Hemorrhagic rectocolitis Autoimmune hepatitis Arthropathic psoriasis Still's disease, other rheumatoid arthritides, juvenile polyarthritides, Rheumatoid arthritis Vasculitides: periarteritis nodosa and related conditions, other necrotizing vasculopathies (periarteritis nodosa, juvenile periarteritis, Churg-Strauss disease, polyangiitis, Kawasaki disease, Horton's disease, Wegener's disease, thrombotic microangiopathy, Takayashu syndrome, Good-Pasture's syndrome, thrombocytopenic purpura) Lupus Polymyositis or dermatopolymyositis Connectivitis (Behcet's disease, Gougerot-Sjöogren syndrome) Inflammatory spondyloarthropathies (APS, spondyloarthritis, other spondyloarthropathies)

Exclusion Criteria

  • •Opposition of the person
  • •Minor patients
  • •Patients under judicial protection

Outcomes

Primary Outcomes

Number of patients living with HIV who have an inflammatory or autoimmune disease

Time Frame: At the end of the study an average of 18 months

Secondary Outcomes

  • Evolution of CD4 and HIV viral load(At the end of the study an average of 18 months)
  • Number of patients on immunosuppressive treatment,(At the end of the study an average of 18 months)
  • Occurrence of infectious complications(At the end of the study an average of 18 months)
  • Number of patients on remission(At the end of the study an average of 18 months)

Investigators

Sponsor
Tourcoing Hospital
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected PatientsAutoimmune Diseases Affecting SkinHIV Infections
NCT03129308Medical University of Vienna842
Active, not recruiting
Not Applicable
Comparison of Inflammatory Markers and Incidence of Comorbidities in Patients on Antiretroviral Therapy With Second-generation Anti-integrase Drugs on Triple Versus Dual TherapyHiv
NCT05699785Centre Hospitalier Universitaire de Nice500
Completed
Not Applicable
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV InfectionAtherosclerosis
NCT01519141University of California, San Francisco579
Completed
Not Applicable
2000 HIV Human Functional Genomics Partnership ProgramHIV Infections
NCT03994835Radboud University Medical Center1,910
Completed
Not Applicable
Inflammasome Activation Via Circulating MetabolitesHuman Immunodeficiency Virus
NCT03191175University Hospital, Bordeaux55
HIV and Inflammatory or Autoimmune... | Clinical Trial